JAK2-positive Philadelphia-negative myeloproliferative neoplasms

Anjali Sharma1, Gurdeep Buxi, Sadhna Marwah

  • 1Department of Pathology, Dr. Ram Manohar Lohia Hospital, PGIMER, New Delhi, India. anjali27sharma@rediffmail.com

Summary

The JAK2 mutation discovery impacts myeloproliferative neoplasms (MPNs) diagnosis and treatment. Clinical, lab, and histology data are crucial for classifying MPNs, even without JAK2 V617F mutations.